Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | DDX3X | O00571 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8427603 | 0.80 | IDO1 (0.49) | RXFP1IDO1BRD9ELANECTRB1 | |
| SCHEMBL13359665 | 0.80 | GAA (0.51) | IDO1ELANECTRB1LMNAL3MBTL1 | |
| SCHEMBL1771858 | 0.77 | IDO1 (0.47) | RXFP1IDO1BRD9ELANECTRB1 | |
| SCHEMBL4708305 | 0.77 | IDO1 (0.44) | RXFP1IDO1BRD9LMNAPOLB | |
| SCHEMBL3783577 | 0.76 | CHRM3 (0.54) | RXFP1BRD9LMNAHSP90AA1HSP90AB1 | |
| SCHEMBL2737224 | 0.76 | NLRP3 (0.56) | RXFP1IDO1LMNAPOLBTP53 | |
| SCHEMBL28360191 | 0.74 | LMNA (0.48) | RXFP1IDO1BRD9ELANECTRB1 | |
| SCHEMBL16791251 | 0.74 | HPGDS (0.49) | LMNAGABRB1GABRB2MAPTCTSS | |
| SCHEMBL22851708 | 0.74 | CTSK (0.46) | GABRB1GABRB2CTSSCTSK | |
| SCHEMBL31226578 | 0.74 | CTSK (0.46) | GABRB1GABRB2CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685721-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230056538-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-02-23 | — | — | US | disclosed |
| US-11192861-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210047275-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192861-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | RXFP1 753/4885IDO1 1586/4885BRD9 4526/4885 |
| US-20210047275-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | RXFP1 753/4885IDO1 1586/4885BRD9 4526/4885 |
| US-20230056538-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | RXFP1 687/4885IDO1 1343/4885BRD9 4450/4885 |
| US-11685721-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | RXFP1 687/4885IDO1 1343/4885BRD9 4450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.